⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063 | 0.97 | — | — | |
| SCHEMBL6273421 | 0.94 | — | — | |
| Bromide SCHEMBL5403925 | 0.94 | — | — | |
| SCHEMBL7608425 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL29110321 | 0.82 | ALDH1A1 (0.45) | — | |
| Hydrochlorthiazide SCHEMBL9106040 | 0.78 | ALDH1A1 (0.36) | — | |
| SCHEMBL102331 | 0.67 | PDPK1 (0.59) | — | |
| SCHEMBL10533757 | 0.67 | ALDH1A1 (0.46) | — | |
| SCHEMBL3568544 | 0.67 | — | — | |
| SCHEMBL28694980 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512091-B2 | Crystal of benzoxazole derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-3816167-B1 | CRYSTAL OF A BENZOXAZOLE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-110003178-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210155630-A1 | CRYSTAL OF BENZOXAZOLE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| EP-3816167-A1 | CRYSTAL OF BENZOXAZOLE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| CN-105431420-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110114358-A | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-110003178-A | Two heteroaryl compounds and application thereof | 豪夫迈·罗氏有限公司 | 2019-07-12 | — | — | CN | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| CN-101405284-A | Pyrimidine, quinazoline, pteridine and derivatives | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001867-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| CN-101142217-A | Imidazopyridazine compounds | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| CN-101023064-A | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMA (US) | 2007-08-22 | — | — | CN | disclosed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |